Common Stock, par value $0.0001 per share
- Symbol
- ENSC
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 9.01 · 8-K/A
Ensysce Biosciences, Inc.
ENSCNASDAQEQUITYCurrent
Financial Statements and Exhibits
Item Financial 9.01 Statements and Exhibits. (d) Exhibits Exhibit Description Number ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 3.3 Certificate of Correction to Certificate of Designation of Series C Non-Voting Convertible Preferred Stock of Ensysce Biosciences, Inc.…
Company context
Current securities
Historical securities (6)
ENSCWOTC · WARRANT · Historical · closed Jun 30, 2026LACQOTC · EQUITY · Historical · closed Jul 1, 2021LACQUOTC · UNIT · Historical · closed Jul 1, 2021LACQUOTC · UNIT · Historical · closed Jul 1, 2021LACQWNASDAQ · WARRANT · Historical · closed Jun 2, 2021LACQWOTC · WARRANT · Historical · closed Jul 2, 2021
Registered securities in this filing
Ensysce Biosciences, Inc. · 8-K/A · Filed 2026-08-06
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item Financial
9.01 Statements and Exhibits.
(d)
Exhibits
Exhibit Description
Number
────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
3.3 Certificate of Correction to Certificate of Designation of Series C Non-Voting Convertible Preferred Stock of Ensysce Biosciences, Inc.
99.1 Press Release of Ensysce Biosciences, Inc.
104 Cover
Page Interactive Data File (embedded within the Inline XBRL document).
Filed exhibits (1)
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS) Up to $77 million in private financing consisting of $21.5 million in private placement financing at initial close plus $17.1 million of Cy Biopharma’s cash and cash equivalents from a pre-acquisition convertible note financing and up to $38.6 million upon achievement of clinical trial milestone Pro forma cash expected to fund CY200 through Phase 2 proof-of-concept data and into registrational development SAN DIEGO, CA, August 6, 2026 -- Ensysce Biosciences, Inc. (NASDAQ: ENSC) (“Ensysce” or the “Company”) today announced it has completed the acquisition of Cy Biopharma, Inc. (“Cy Biopharma”), a privately held, clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain. Concurrent with the acquisition that brought in $17.1 million in cash from a pre-acquisition convertible note financing, Ensysce en…
Open exhibit ↗